Literature DB >> 17416324

Severe visual impairment in children with mild or moderate retinal residua following regressed threshold retinopathy of prematurity.

R Michael Siatkowski1, Velma Dobson, Graham E Quinn, C Gail Summers, Earl A Palmer, Betty Tung.   

Abstract

PURPOSE: To describe clinical features of patients from the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) trial who, after developing severe ROP in infancy, had minimal or moderate retinal residua in at least one eye but a visual acuity of worse than 20/200 in both eyes at the 10 year examination.
METHODS: Data from the 10 year CRYO-ROP Trial follow-up exams were evaluated to identify all patients with retinal outcomes of no retinopathy of prematurity (ROP) residua, straightened temporal vessels, or macular heterotopia in at least one eye, but visual acuity less than 20/200 in both eyes. Presence of optic atrophy, nystagmus, and optic disk cupping and developmental survey results were examined.
RESULTS: Of 247 patients examined at 10 years, 16 met our inclusion criteria. At the last age at which the following data were recorded, seven had optic atrophy at the 10 year examination, one had optic disk cupping >0.5 at the 5(1/2) year examination, and eight had nystagmus under binocular conditions at the 24 month examination. Nine patients had a below-normal developmental test score on the Functional Independence Measure for Children (WeeFIM). After clinical data interpretation, we concluded that the predominant cause of visual impairment was postgeniculate disease in five patients, ROP in six patients, and combined anterior and posterior visual pathway disease in two patients; in three patients data were insufficient to make a determination.
CONCLUSIONS: Poor visual function with mild to moderate retinal residua of severe ROP in at least one eye is relatively rare. In such patients, anterior, posterior, or combined visual pathway disease can occur.

Entities:  

Mesh:

Year:  2007        PMID: 17416324     DOI: 10.1016/j.jaapos.2006.11.113

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  7 in total

1.  Final visual acuity results in the early treatment for retinopathy of prematurity study.

Authors:  William V Good; Robert J Hardy; Velma Dobson; Earl A Palmer; Dale L Phelps; Betty Tung; Maryann Redford
Journal:  Arch Ophthalmol       Date:  2010-04-12

2.  [Analysis of choroidal thickness in AP-ROP, threshold disease and ROP without laser photocoagulation].

Authors:  G Gökgöz-Özisik; Imren Akkoyun; S Oto; S A Bayar; A Tarcan; Z Kayhan; G Yilmaz
Journal:  Ophthalmologe       Date:  2016-01       Impact factor: 1.059

3.  Idiopathic maculopathy in eyes with regressed retinopathy of prematurity.

Authors:  Kyoung Min Lee; Jeong Hun Kim; Young Suk Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-23       Impact factor: 3.117

4.  Clinical characteristics of children with severe visual impairment but favorable retinal structural outcomes from the Early Treatment for Retinopathy of Prematurity (ETROP) study.

Authors:  R Michael Siatkowski; William V Good; C Gail Summers; Graham E Quinn; Betty Tung
Journal:  J AAPOS       Date:  2013-03-21       Impact factor: 1.220

5.  Glaucoma in the Early Treatment for Retinopathy of Prematurity (ETROP) study.

Authors:  Don L Bremer; David L Rogers; William V Good; Betty Tung; Robert J Hardy; Rae Fellows
Journal:  J AAPOS       Date:  2012-10       Impact factor: 1.220

Review 6.  Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies.

Authors:  José Carlos Rivera; Mari Holm; Dordi Austeng; Tora Sund Morken; Tianwei Ellen Zhou; Alexandra Beaudry-Richard; Estefania Marin Sierra; Olaf Dammann; Sylvain Chemtob
Journal:  J Neuroinflammation       Date:  2017-08-22       Impact factor: 8.322

7.  Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions.

Authors:  Lara Carroll; Leah A Owen
Journal:  Explor Med       Date:  2020-02-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.